戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 y logistic regression analysis was performed double-blind.
2                          In this randomized, double-blind, 2-dose gluten-challenge trial conducted in
3                                   We did two double-blind, active-controlled studies (now in open-lab
4                     TARGET was a randomized, double-blind, active-controlled, parallel-group, multice
5                         This parallel-group, double-blind, active-controlled, phase-3b, multicentre (
6                                        Using double-blind analysis, we assessed the presence of signs
7                             This randomized, double-blind, ancillary trial of the Zurich Multiple End
8               Using a crossover, randomized, double-blind and placebo-controlled trial design, 16 hea
9 ne/haloperidol), or placebo in a randomized, double-blind, between-subjects design.
10                     This is a randomized and double-blind clinical trial to evaluate the efficacy of
11      We randomized 40 SCZ non-smokers into a double-blind clinical trial with four groups: placebo, 5
12                      In this parallel-group, double-blind clinical trial, participants were randomize
13 mined in a randomized controlled trial under double-blind conditions for 10-days at doses of 80 or 32
14 onducted within the context of a randomized, double-blind, controlled clinical trial to assess whethe
15                    In this 24-week, phase 3, double-blind, controlled trial, we randomly assigned pat
16        We conducted a multisite, randomized, double-blinded, controlled trial to examine the effectiv
17                          Here we report on a double-blinded, controlled trial, where 161 healthy norm
18 us administration of ketamine 0.5 mg/kg in a double-blind cross-over design with treatment days separ
19 eive once-weekly alendronate or placebo in a double-blind cross-over study designed to assess the saf
20 n this field, such as utilizing a randomized double-blind crossover design, enrolling participants li
21 ask at least 8 days apart using a randomised double-blind crossover design.
22                                  This larger double-blind crossover study that included healthy contr
23 dults (n = 64) participated in a randomized, double-blind, crossover intervention.
24      In 2 separate 4-wk, placebo-controlled, double-blind, crossover trials, 50 healthy adults with l
25 iabetes to a randomized, placebo-controlled, double-blinded, crossover, double-dummy study comprising
26                                         In a double-blind design, 70 healthy volunteers were randomly
27                                A randomized, double-blind, dose-escalation design was employed.
28                               We performed a double-blind, dose-response, randomized, cross-over nutr
29          We conducted a 26-week, randomized, double-blind, double-dummy, phase 2 trial to investigate
30                                       In two double-blind, double-dummy, phase 3 trials, we randomly
31                   We conducted the phase III double-blind European Organisation for Research and Trea
32                          In this randomized, double-blind, event-driven trial, we assigned 4822 patie
33          We conducted a phase 3 multicenter, double-blind, event-driven, randomized-withdrawal trial
34 e clearance >=50 ml/min were randomized in a double-blind fashion to rivaroxaban 10 mg or placebo dai
35 oxytocin (20 IU), and placebo in randomized, double-blind fashion.
36 focus on the use of un-bias patient cohorts, double-blinded index test and detection assays that do n
37 essor pain tolerance before and 40-min after double-blind injection of .08 mg/kg morphine or placebo.
38 ngual film or matching placebo in a 12-week, double-blind maintenance phase.
39  until patients were randomly assigned, in a double-blind manner, to groups that received 4 months of
40 from 36 centers were randomly assigned, in a double-blind manner, to groups that received biweekly in
41 ary 2012 through October 2017, a randomized, double-blinded multicenter clinical trial was conducted
42        This study is an ongoing, randomised, double-blind, multicentre, active-controlled, phase 3, n
43 reased Cardiovascular RisK) is a randomized, double-blind, multinational trial comparing monthly subc
44 s international, parallel-group, randomized, double-blind, noninferiority trial, we randomly assigned
45                            This multicentre, double-blind, parallel-arm, randomised controlled trial
46                                         In a double-blind, parallel-group randomised trial, we recrui
47 , AND PARTICIPANTS: Multicenter, randomized, double-blind, parallel-group trial conducted at 74 inten
48 is phase 2, multicenter, placebo-controlled, double-blind, parallel-group trial, we randomly assigned
49      This was a phase II placebo-controlled, double-blind, parallel-group, enriched enrollment random
50                             This randomised, double-blind, parallel-group, multicentre placebo-contro
51 TORE BRAIN was an international, randomised, double-blind, parallel-group, placebo-controlled, multic
52                       In this single-centre, double-blind, parallel-group, randomised trial, patients
53 IGN, SETTING, AND PARTICIPANTS: Multicenter, double-blind, parallel-group, randomized clinical trial
54                                       In the double-blind period, median progression-free survival wa
55  conducted a randomized, placebo-controlled, double-blind pharmacological study testing the impact of
56                               We performed a double-blind phase 2 trial of 104 patients with NAFLD in
57         In a randomized, placebo-controlled, double-blind phase II trial (SORMAIN; German Clinical Tr
58 ry with curative intent were included in our double-blind phase III multicenter trial.
59                              In PARADIGMS, a double-blind phase III trial in 215 paediatric patients
60                                          The double-blind phase was due to last until 44 protocol-def
61                                       In the double-blind phase, similar proportions of patients in e
62 rotocol-defined relapse or at the end of the double-blind phase.
63      In this randomised, placebo-controlled, double-blind, phase 1 trial, participants were enrolled
64                             In this ongoing, double-blind, phase 1-3 trial involving nonhospitalized
65 domised, parallel-group, placebo-controlled, double-blind, phase 1/2a study (TRAVERSE) was done at 11
66                                         In a double-blind, phase 1b clinical trial, we assessed the e
67 : This was a randomized, placebo-controlled, double-blind, phase 2 clinical trial to assess the vacci
68            We did a multicentre, randomised, double-blind, phase 2 study for adult patients with viti
69                               We performed a double-blind, phase 2 trial in adults with moderate to s
70          We conducted a 12-week, randomized, double-blind, phase 2 trial of nemolizumab (at a dose of
71                                      In this double-blind, phase 2b/3 trial, adults (aged 18-75 years
72   Previously, findings from CheckMate 238, a double-blind, phase 3 adjuvant trial in patients with re
73      In this randomised, placebo-controlled, double-blind, phase 3 trial, done in 209 sites in 29 cou
74      In this randomised, placebo-controlled, double-blind, phase 3 trial, done in 246 academic centre
75                                      In this double-blind, phase 3 trial, men with nonmetastatic, cas
76                          In this randomized, double-blind, phase 3 trial, we assigned, in a 2:1 ratio
77                      Randomized, controlled, double-blind, phase 3 trial.
78                             This randomised, double-blind, phase 3, placebo-controlled, multicentre t
79                   We conducted a randomized, double-blind, Phase II placebo-controlled trial of a mon
80                         In this multicenter, double-blind, phase III study, 418 patients with previou
81 depressant lead-ins without placebo or using double-blind placebo was very poor (<15%).
82 label antidepressant without placebo or with double-blind placebo) nearly futile.
83                       Participants underwent double-blind placebo-controlled food challenge to peanut
84 ersus placebo to asthmatics in a randomized, double-blind placebo-controlled investigation.
85                      REWIND is a randomised, double-blind placebo-controlled trial at 371 sites in 24
86                       A phase 1-2 randomized double-blind placebo-controlled trial enrolled 252 parti
87   The authors conducted an 8-week randomized double-blind placebo-controlled trial of adjunctive test
88            We performed the first randomized double-blind placebo-controlled trial to evaluate effica
89 Day 14.Methods: In a multicenter, randomized double-blind placebo-controlled trial, we studied retrea
90 ther these are causally linked, ideally in a double-blind placebo-controlled trial.
91                    We conducted a randomized double-blinded placebo-controlled trial to determine the
92                  Analysis of patients from a double-blind, placebo-controlled allergen-specific immun
93 Exacerbations (VDKA) Study was a randomized, double-blind, placebo-controlled clinical trial of vitam
94                  This study is a randomized, double-blind, placebo-controlled clinical trial.
95  rhythms.(9) In a preregistered, randomized, double-blind, placebo-controlled crossover design in 25
96 h empagliflozin and placebo in a randomized, double-blind, placebo-controlled crossover study.
97                                      A pilot double-blind, placebo-controlled crossover trial was con
98 ropranolol (40 mg) using a between-subjects, double-blind, placebo-controlled design.
99                                      In this double-blind, placebo-controlled experimental medicine s
100                     Efficacy was assessed by double-blind, placebo-controlled food challenge (5044 mg
101 red PEOPLE, of whom 141 (71%) had assessable double-blind, placebo-controlled food challenge at month
102 ne; and 13.5% (19 of 141) tolerated the full double-blind, placebo-controlled food challenge of 5444
103 DBV712 250 mug in PEPITES underwent month-36 double-blind, placebo-controlled food challenge with an
104  BE-reactive underwent egg OIT and identical double-blind, placebo-controlled food challenges as a co
105                 The second was a randomized, double-blind, placebo-controlled pharmacologic intervent
106                                         This double-blind, placebo-controlled phase 2b trial compared
107                 IMspire150 was a randomised, double-blind, placebo-controlled phase 3 study done at 1
108                   We conducted a randomized, double-blind, placebo-controlled phase 3 trial in 1154 p
109                                          The double-blind, placebo-controlled phase of the study ende
110                     This was a single-center double-blind, placebo-controlled prospective study condu
111      We performed a multicentre, randomised, double-blind, placebo-controlled randomised trial in 39
112 ondary outcome of the ProPrems multi-center, double-blind, placebo-controlled randomized trial (ANZCT
113 cally Manage Acute Coronary Syndromes) was a double-blind, placebo-controlled randomized trial conduc
114 RD-4 and FORWARD-5: two phase 3, randomized, double-blind, placebo-controlled studies that utilized t
115 omen with HIV participating in a randomized, double-blind, placebo-controlled study comparing 28 week
116                   Methods: This prospective, double-blind, placebo-controlled study enrolled 10 patie
117                       The MS-SPI randomised, double-blind, placebo-controlled study found that MD1003
118     This single-center, phase 2, randomized, double-blind, placebo-controlled study investigated the
119    We describe a first-in-human, randomized, double-blind, placebo-controlled study investigating the
120            In a Phase I, randomized, partial double-blind, placebo-controlled study of 36 malaria-nai
121 cted from lesional and nonlesional skin in a double-blind, placebo-controlled study of 54 patients wi
122                      This was a multicenter, double-blind, placebo-controlled study randomizing subje
123                                This phase 3, double-blind, placebo-controlled study was done at 118 s
124                             This randomised, double-blind, placebo-controlled study was done by movem
125                                      In this double-blind, placebo-controlled study, we investigated
126 th irritable bowel syndrome in a randomised, double-blind, placebo-controlled study.
127       We designed a multicenter, randomized, double-blind, placebo-controlled trial (the SUGAR-DM-HF
128 DeltaNS2/Delta1313/I1314L was evaluated in a double-blind, placebo-controlled trial (vaccine-placebo
129                   We conducted a randomized, double-blind, placebo-controlled trial across the United
130 We did a multicentre, phase 2/3, randomised, double-blind, placebo-controlled trial at 92 sites in th
131                     We did a large, phase 2, double-blind, placebo-controlled trial at three sites in
132           ODYSSEY OUTCOMES was a randomized, double-blind, placebo-controlled trial comparing alirocu
133                                         In a double-blind, placebo-controlled trial enrolling females
134    VOYAGER PAD was a phase 3, international, double-blind, placebo-controlled trial in patients with
135 y on inflammation and immune activation in a double-blind, placebo-controlled trial in PWH at moderat
136                       This was a randomized, double-blind, placebo-controlled trial in which patients
137                             This randomized, double-blind, placebo-controlled trial included patients
138          This was a multicenter, randomized, double-blind, placebo-controlled trial involving 17 hosp
139                    FOURIER was a randomized, double-blind, placebo-controlled trial involving patient
140                   We performed a randomized, double-blind, placebo-controlled trial involving patient
141     To test this, we conducted a randomized, double-blind, placebo-controlled trial of pioglitazone t
142         We performed a 12-month, randomized, double-blind, placebo-controlled trial of pomegranate ju
143                                  Randomized, double-blind, placebo-controlled trial of single dose re
144                       This was a randomised, double-blind, placebo-controlled trial of vitamin D(3) s
145         We conducted a randomized, adaptive, double-blind, placebo-controlled trial that enrolled pat
146                   We conducted a randomized, double-blind, placebo-controlled trial to assess whether
147          We conducted a 24-week, randomized, double-blind, placebo-controlled trial to evaluate the e
148                     A factorial, randomized, double-blind, placebo-controlled trial was conducted in
149 cipants for this randomised, parallel-group, double-blind, placebo-controlled trial were recruited vi
150             We hence conducted a randomized, double-blind, placebo-controlled trial with newly diagno
151 GN, SETTING, AND PARTICIPANTS: A randomized, double-blind, placebo-controlled trial, conducted at 190
152                  We performed a multicenter, double-blind, placebo-controlled trial, from March 2016
153 nt Ethyl-Intervention Trial), a multicenter, double-blind, placebo-controlled trial, randomly assigne
154 and Safety Cardiovascular Outcomes Trial), a double-blind, placebo-controlled trial, randomly assigne
155                 In this phase 3, randomized, double-blind, placebo-controlled trial, we assigned 5050
156                    In a phase 2, randomized, double-blind, placebo-controlled trial, we randomly assi
157     IBIS-II is an international, randomised, double-blind, placebo-controlled trial.
158 f patients with frequent episodes of IA in a double-blind, placebo-controlled trial.
159 ding (HALT-IT): an international randomised, double-blind, placebo-controlled trial.
160  participants volunteered in this randomized double-blind, placebo-controlled, between-group study.
161 1; 1 female) completed a phase-1 randomized, double-blind, placebo-controlled, crossover study to exa
162                 This study was a randomized, double-blind, placebo-controlled, crossover trial in 223
163  questions were explored in the context of a double-blind, placebo-controlled, crossover trial of ket
164 iuretics in Heart Failure) was a randomized, double-blind, placebo-controlled, crossover trial of pat
165 virus-naive, healthy adults in a randomized, double-blind, placebo-controlled, dose-escalation Phase
166                  BE ACTIVE was a randomised, double-blind, placebo-controlled, dose-ranging phase 2b
167    The MAVERICK-HCM trial was a multicenter, double-blind, placebo-controlled, dose-ranging phase II
168                   We conducted a randomized, double-blind, placebo-controlled, dose-ranging trial inv
169                         We did a randomised, double-blind, placebo-controlled, event-driven trial of
170 TING, AND PARTICIPANTS: Phase 2b randomized, double-blind, placebo-controlled, multicenter trial of 7
171 -pollen-allergic patients were enrolled in a double-blind, placebo-controlled, multicenter trial usin
172  In this investigator-initiated, randomized, double-blind, placebo-controlled, multicenter trial, pat
173                                  Following a double-blind, placebo-controlled, parallel group design,
174           DESIGN, SETTING, AND PARTICIPANTS: Double-blind, placebo-controlled, parallel randomized tr
175                   A single site, randomized, double-blind, placebo-controlled, parallel study was con
176                             In a randomized, double-blind, placebo-controlled, parallel-group phase 1
177                         We did a randomised, double-blind, placebo-controlled, phase 2 trial in 20 Ge
178                                      In this double-blind, placebo-controlled, phase 2 trial, 140 pat
179                                      In this double-blind, placebo-controlled, phase 2 trial, we enro
180 RTICIPANTS: CAPACITY HFpEF was a randomized, double-blind, placebo-controlled, phase 2 trial.
181                This multicentre, randomised, double-blind, placebo-controlled, phase 3 study included
182                    COMBI-AD is a randomised, double-blind, placebo-controlled, phase 3 trial comparin
183                   BROCADE3 was a randomised, double-blind, placebo-controlled, phase 3 trial done at
184                                      In this double-blind, placebo-controlled, phase 3 trial, we rand
185                                         In a double-blind, placebo-controlled, phase 3 trial, we rand
186                                      In this double-blind, placebo-controlled, phase 3 trial, we rand
187                This randomized, multicenter, double-blind, placebo-controlled, phase III trial was co
188                                   RV306 is a double-blind, placebo-controlled, randomised clinical tr
189                                      Using a double-blind, placebo-controlled, randomized crossover d
190 port the results from a multicenter, 8-week, double-blind, placebo-controlled, randomized trial in pa
191                             We designed this double-blind, placebo-controlled, randomized trial to de
192                                In this 4-mo, double-blind, placebo-controlled, randomized trial, 244
193                              In a randomized double-blind, placebo-controlled, time course SLIT study
194                         We did a randomised, double-blind, placebo-controlled, trial at 32 health cen
195                                A randomized, double-blind, placebo-controlled, two-way crossover stud
196                   We performed a randomized, double-blinded, placebo-controlled trial of 5110 adults
197                                A randomized, double-blinded, placebo-controlled, crossover interventi
198 bjects without diabetes were recruited for a double-blinded, placebo-controlled, crossover study incl
199        Healthy volunteers were enrolled in a double-blinded, placebo-controlled, crossover study, and
200                 This investigator-initiated, double-blinded, placebo-controlled, randomized trial enr
201 agonist) or placebo across two sessions in a double-blinded pseudo-randomised crossover design.
202                                              Double-blind randomised controlled trials comparing cloz
203                                  We enrolled double-blind, randomised controlled trials (RCTs).
204                         In this multicentre, double-blind, randomised phase 3 trial (JADE MONO-1), pa
205                AFFIRM-AHF was a multicentre, double-blind, randomised trial done at 121 sites in Euro
206                            This multicentre, double-blind, randomised, controlled, phase 3 trial was
207 ved 10 mg zolpidem or placebo according to a double-blind, randomised, cross-over design.
208                  HPTN 077 was a multicentre, double-blind, randomised, placebo-controlled phase 2a tr
209 h active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 tri
210                        For this multicentre, double-blind, randomised, placebo-controlled study done
211                        We did a multicentre, double-blind, randomised, placebo-controlled, dose-respo
212                                      In this double-blind, randomised, placebo-controlled, phase 3 st
213                       In this international, double-blind, randomised, placebo-controlled, phase 3 st
214  ORATORIO was an international, multicentre, double-blind, randomised, placebo-controlled, phase 3 tr
215                                   This was a double-blind, randomised, placebo-controlled, phase 3 tr
216                                   A 24-week, double-blinded, randomised, placebo-controlled trial (Cl
217                  This prospective randomized double blinded randomized controlled trial has revealed
218                          In this multicentre double-blind randomized clinical trial, we investigated
219                      Multicentre prospective double-blind randomized controlled trial of 3 methods of
220         This study was a parallel, dual-arm, double-blind randomized controlled trial.
221                                              Double-blind randomized placebo-controlled clinical tria
222                       FMT-TRIM was a 12-week double-blind randomized placebo-controlled pilot trial o
223           DESIGN, SETTING, AND PARTICIPANTS: Double-blinded randomized clinical trial in 2 tertiary N
224                                         In a double-blinded randomized sequence, participants consume
225         DESIGN, SETTING, AND PARTICIPANTS: A double-blind, randomized clinical trial conducted in 6 h
226                               We performed a double-blind, randomized clinical trial enrolling 180 wo
227 EER-HF trial was a prospective, multicenter, double-blind, randomized clinical trial enrolling 881 pa
228                                    Six-month double-blind, randomized clinical trial in which partici
229                                      In this double-blind, randomized controlled equivalence trial, i
230 Graft Angioplasty; NCT01121224) prospective, double-blind, randomized controlled trial.
231                             We conducted two double-blind, randomized crossover experiments in which
232                        In the multinational, double-blind, randomized LEADER trial, 9,340 patients wi
233 ients in CKD, we conducted a parallel-group, double-blind, randomized trial in participants aged 18 o
234                                      In this double-blind, randomized trial, we recruited 88 hospital
235                                            A double-blind, randomized, controlled crossover 12-wk int
236                                   A 12-week, double-blind, randomized, controlled proof-of-concept tr
237 -105) for Helicobacter pylori eradication: a double-blind, randomized, controlled trial.
238                               We conducted a double-blind, randomized, counterbalanced, crossover stu
239 o were unrestrained eaters participated in a double-blind, randomized, crossover study at a contract
240 ers were analyzed as secondary outcomes of a double-blind, randomized, milk-based vitamin D intervent
241                We conducted a single-center, double-blind, randomized, parallel-group trial in patien
242                               We conducted a double-blind, randomized, placebo-controlled noninferior
243  to PSC, PBC, or SSC were recruited for this double-blind, randomized, placebo-controlled trial betwe
244        The results of our recently published double-blind, randomized, placebo-controlled trial of es
245                                         In a double-blind, randomized, placebo-controlled trial, we e
246                  We conducted two identical, double-blind, randomized, placebo-controlled, 6-month ph
247                                            A double-blind, randomized, placebo-controlled, crossover
248               We conducted an international, double-blind, randomized, placebo-controlled, parallel-g
249 c IgG(4) (sIgG(4)), in a large, single-site, double-blind, randomized, placebo-controlled, phase 2 pe
250                                 Part 1 was a double-blind, randomized, placebo-controlled, single asc
251                               In the present double-blind, randomized, sham-controlled trial, 105 pat
252 y-one adolescents with TS were enrolled in a double-blind, randomized, sham-controlled, crossover stu
253 IGN, SETTING, AND PARTICIPANTS: Multicenter, double-blinded, randomized clinical trial at 20 trauma c
254 volunteers (15 females) participated in this double-blinded, randomized, placebo-controlled trial.
255 this 12-week, single-center, parallel-group, double-blind RCT and randomized into 4 arms (n = 23): HP
256                         In this multicentre, double-blind, response-adaptive, randomised controlled t
257 NG, AND PARTICIPANTS: Multicenter randomized double-blind sequential trial conducted in France, with
258                               We conducted a double-blind sham-controlled study on 20 human volunteer
259 ement initiation.SIGNIFICANCE STATEMENT This double-blind sham-controlled study suggested that neurof
260                                              Double-blinded sham-controlled trials are needed to conf
261                                         This double-blind, sham-controlled, randomised controlled tri
262                 Using a within-participants, double-blinded, sham-controlled crossover design, we rec
263                               We performed a double-blind study of 78 patients with NASH at 9 centers
264 ith anxiety from an LTI were randomized in a double-blind study to receive MDMA (125 mg, n = 13) or p
265                                         In a double-blinded study with 132 pond water samples, we est
266  treatment and sustained for the duration of double-blind therapy.
267       SORCE is an international, randomized, double-blind, three-arm trial of sorafenib after surgica
268 ne days per month in the last 4 weeks of the double-blind treatment phase (weeks 9-12).
269  for at least one 4-week interval during the double-blind treatment phase were analysed for efficacy.
270 tching placebo every other day for 12 weeks (double-blind treatment phase).
271  no difference between treatment arms during double-blind treatment, but during the open-label period
272 fficacy and safety results up to 52 weeks of double-blind treatment.
273 thma before and after 12 weeks of randomized double-blinded treatment with lebrikizumab (n = 31) or p
274 ARTICIPANTS: Randomized, placebo-controlled, double-blind trial conducted at 2 US academic hospitals
275                  We conducted a multicenter, double-blind trial in which patients with type 2 diabete
276                  We performed a multicenter, double-blind trial in which patients with type 2 diabete
277                               We performed a double-blind trial of 190 patients with IBS (according t
278                               We conducted a double-blind trial of SER-287 in 58 adults with active m
279                               We performed a double-blind trial to compare the efficacy and safety of
280                   We performed a multicenter double-blind trial to investigate the efficacy of 3 aspi
281 lled, four-sequence, four-period, crossover, double-blind trial, patients with multiple sclerosis who
282                                         In a double-blind trial, patients with peripheral artery dise
283 ascular markers, we conducted a multicenter, double-blind trial, randomizing 278 participants with st
284                              In this phase 3 double-blind trial, the authors evaluated the weight pro
285                 In a randomized, controlled, double-blind trial, we assigned patients with chronic co
286                             In a randomized, double-blind trial, we compared hydroxyurea at a fixed d
287                                      In this double-blind trial, we randomly assigned 5734 patients w
288                            In this phase 2b, double-blind trial, we randomly assigned adults with pla
289                                         In a double-blind trial, we randomly assigned participants wi
290                             In this phase 3, double-blind trial, we randomly assigned, in a 1:1 ratio
291                          In this randomized, double-blind trial, which consisted of a 56-week treatme
292 domized, placebo-controlled, parallel-group, double-blinded trial (LIPCAL-ALS study) was conducted be
293                                 A randomised double-blinded trial of 3 pyrethroid LLIN products (10,5
294       In this randomized, active-controlled, double-blinded trial, 444 adults 60 through 64 years of
295 nalysis was conducted for 3 doravirine (DOR) double-blind trials (Phase IIb: P007 [NCT01632345]; Phas
296 h either basic pH 8.5 or pH 5.5) was applied double-blinded twice daily to 6 AD patients and 6 health
297 nfavorable cardiometabolic risk markers, but double-blinded vitamin D intervention studies in childre
298         DESIGN, SETTING, AND PARTICIPANTS: A double-blind, within-participants, randomized clinical t
299 g either placebo or 20 mg memantine po, in a double-blind, within-subject cross-over random order des
300 tagonist S-ketamine in a placebo-controlled, double-blind, within-subject fashion.

 
Page Top